{"organizations": [], "uuid": "1213a48895a3759d69fce6c21e681cbf6576d211", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180517.html", "section_title": "Archive News &amp; Video for Thursday, 17 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biolinerx-to-present-overall-survi/brief-biolinerx-to-present-overall-survival-data-at-eha-from-phase-2a-study-of-bl-8040-in-r-r-aml-patients-idUSFWN1SO0UV", "country": "US", "domain_rank": 408, "title": "BRIEF-Biolinerx To Present Overall Survival Data At Eha From Phase 2A Study Of Bl-8040 In R/R Aml Patients", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.661, "site_type": "news", "published": "2018-05-17T21:43:00.000+03:00", "replies_count": 0, "uuid": "1213a48895a3759d69fce6c21e681cbf6576d211"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biolinerx-to-present-overall-survi/brief-biolinerx-to-present-overall-survival-data-at-eha-from-phase-2a-study-of-bl-8040-in-r-r-aml-patients-idUSFWN1SO0UV", "ord_in_thread": 0, "title": "BRIEF-Biolinerx To Present Overall Survival Data At Eha From Phase 2A Study Of Bl-8040 In R/R Aml Patients", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "bioline rx ltd", "sentiment": "negative"}, {"name": "aml", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 17 (Reuters) - BioLine RX Ltd:\n* BIOLINERX TO PRESENT OVERALL SURVIVAL DATA AT EHA FROM PHASE 2A STUDY OF BL-8040 IN R/R AML PATIENTS\n* BIOLINE RX LTD - BL-8040 IN COMBINATION WITH CYTARABINE SHOWED SIGNIFICANTLY IMPROVED OVERALL SURVIVAL COMPARED TO HISTORICAL DATA IN TRIAL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-17T21:43:00.000+03:00", "crawled": "2018-05-18T19:40:46.000+03:00", "highlightTitle": ""}